# Mounjaro and Zepbound Cut Death Risk in Heart Disease Patients
Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, reduces death risk in people with serious heart conditions, according to new research. The drugs lowered mortality by 38% in patients with heart failure and preserved ejection fraction (HFpEF), a condition where the heart stiffens and fails to relax properly.
Researchers studied 521 patients with HFpEF over 12 weeks. Those receiving tirzepatide showed improved heart function and lost an average of 8 pounds. The control group saw no improvement.
HFpEF affects roughly 3.1 million Americans and has limited treatment options. Current medications don't significantly extend survival. Tirzepatide works differently. The drug targets two hormone receptors that regulate blood sugar and appetite, which also influence heart muscle function and inflammation.
Cardiologists call this a breakthrough for a frustrating condition. "This is genuinely novel," one researcher stated. The drugs belong to a class called GLP-1 receptor agonists, originally developed for type 2 diabetes.
However, tirzepatide carries known side effects including nausea and vomiting. Patients also require ongoing injections. More research is needed to confirm these findings in larger populations and longer-term studies.
The results suggest tirzepatide may become the first medication that actually improves survival rates in HFpEF patients.